World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 19 February 2015
Main ID:  NCT01194232
Date of registration: 01/09/2010
Prospective Registration: Yes
Primary sponsor: Children's Hospital Medical Center, Cincinnati
Public title: Sildenafil Trial in Children and Young Adults With CF
Scientific title: Randomized Controlled Study of Sildenafil in Children and Young Adults With Mild to Moderate Cystic Fibrosis Lung Disease
Date of first enrolment: August 2012
Target sample size: 0
Recruitment status: Withdrawn
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 1/Phase 2
Countries of recruitment
United States
Key inclusion & exclusion criteria

Inclusion Criteria

Research subjects must meet the following inclusion criteria:

- Age 8 years to age 21 years

- Weight > 20kg

- Diagnosis of cystic fibrosis confirmed by a prior sweat chloride evaluation of > 60
mmol/liter or by two identified CFTR mutations on genetic analysis

- Able to perform acceptable and repeatable spirometry per American Thoracic
Society/European Respiratory Society (ATS/ERS) joint consensus criteria.

- Have valid spirometry data for at least 3 years

- Must have mild to moderate lung disease (Mild lung disease will be defined as an
FEV1%p of 80-99% predicted. Moderate lung disease will be defined as an FEV1%p of
60-79% predicted.)

- If under the age of 18, the subject must assent to participation in the study, and
the subject's parent or guardian must be able to give written informed consent and
comply with the requirements of the study protocol

- If 18 years of age or older, the subject must be able to give written parental
permission and comply with the requirements of the study protocol

- For female subjects: negative serum pregnancy test and must be willing to use
contraception during study participation

- Able to tolerate MRI without sedation

- Subjects who are on alternating monthly on/off cycles of inhaled antibiotics must be
willing to be off of inhaled antibiotic therapy for one "on" cycle.

- Must be currently enrolled in CCHMC IRB#: 2008-0926

- Normal Vitamin K status (PT/IND, PIVKA, etc) at screening

Exclusion Criteria

Research subjects will be excluded from the study based on:

- History of CF-related liver disease with portal hypertension

- Currently smoking cigarettes or other tobacco products

- Use of daytime oxygen supplementation

- Previous organ transplantation

- Unstable or uncontrolled hypertension

- Ongoing use of oral corticosteroids

- For female subjects: pregnancy or lactation and unwillingness to use contraception
during study participation

- Any hemodynamically significant congenital or acquired cardiac disease or significant
cardiomyopathy, hematologic disease (i.e. hemoglobinopathies), or pulmonary disease
associated with an increased risk of pulmonary perfusion defects or pulmonary
hypertension other than as an outcome of CF

- History of renal and/or hepatic insufficiency, defined as cystatin-C level that
exceeds normal range and a previous diagnosis of liver cirrhosis.

- History of uncontrolled asthma defined as oral steroid dependent

- History of hypersensitivity to gadolinium (Magnevist)

- Contraindications specific to MRI including a history of claustrophobia, cardiac
pacemaker, or other non-MRI compatible surgical implants (This includes
neuro-stimulators containing electrical circuitry, or which generate electrical
signals and/or have moving metal parts, and metal orthopedic pins or plates. The
research coordinator and/or the MRI technologist will screen all subjects using the
standard checklist of medical history and safety questions used by the Radiology
Department in routine clinical scans.)

- Daily use of montelukast and ibuprofen

- Use of nitrate medicines or other drugs known to have unsafe interactions with

- Known allergy to Sildenafil

- Inability to comply with study procedures

- History of the following:

1. Tinnitus or hearing impairment

2. CF exacerbation within the preceding two months

3. Ulcer, severe gastritis, or prior GI bleed

4. Recurrent epistaxis

5. Diabetes or abnormal OGTT (risk of retinal hemorrhage with sildenafil is highest
in diabetics)

Laboratory Exclusion Criteria for research subjects (based on history or blood work before
first MRI):

- Positive sputum, epiglottic, or bronchoalveolar lavage culture for Mycobacterium
abscessus during the 2 years prior to enrollment

- A positive serum pregnancy test

- Serum creatinine > two times the upper limit of normal for age

- A serum Cystatin C < 60 ml/min/1.73m2

- Vitamin K outside of normal range

Age minimum: 8 Years
Age maximum: 21 Years
Gender: Both
Health Condition(s) or Problem(s) studied
CMRI of Lung Perfusion
Cystic Fibrosis With Mild to Moderate Lung Disease
Lung Perfusion
Lung Vascularization
Drug: Sildenafil
Primary Outcome(s)
Increase pulmonary perfusion [Time Frame: 8 week visit]
Secondary Outcome(s)
Improved lung function [Time Frame: 8 weeks]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history